Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EPO Products Set To Boost Future Revenue For 3SBio

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - 3SBio generated revenues from increased sales of its recombinant human erythropoietin products but saw its earnings slip, according to the unaudited financial results for the second quarter ended June 30

You may also be interested in...



Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery

BEIJING - Stung by a loss of nearly $3 million in late 2008 tied to the U.S. financial meltdown, leading Chinese biopharmaceutical outfit 3SBio is laying the drug development groundwork for a profit rebound this year and next

Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery

BEIJING - Stung by a loss of nearly $3 million in late 2008 tied to the U.S. financial meltdown, leading Chinese biopharmaceutical outfit 3SBio is laying the drug development groundwork for a profit rebound this year and next

Malaysia Releases Regulatory Guidance On Biosimilars, But Local Manufacturers Not Ready To Produce - Analyst

PERTH, Australia - Malaysia's Ministry of Health released guidelines for registering biosimilars in Malaysia last month - making Malaysia likely the first Southeast Asian nation to set a regulatory framework for the new breed of follow-on biologics

Related Content

Latest News
UsernamePublicRestriction

Register

SC069315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel